Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 326

1.

The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.

Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA.

J Pharm Pharmacol. 2005 Nov;57(11):1407-13.

PMID:
16259772
2.

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

Zhou H, Mayer PR, Wajdula J, Fatenejad S.

J Clin Pharmacol. 2004 Nov;44(11):1235-43.

PMID:
15496641
3.

Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.

Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C.

Br J Clin Pharmacol. 2006 Oct;62(4):435-45.

4.

Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.

Zhou H, Buckwalter M, Boni J, Mayer P, Raible D, Wajdula J, Fatenejad S, Sanda M.

Int J Clin Pharmacol Ther. 2004 May;42(5):267-76.

PMID:
15176649
5.

Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin.

Goldstein SL, Leung JC, Silverstein DM.

Clin J Am Soc Nephrol. 2006 Sep;1(5):979-86. Epub 2006 Aug 16.

6.

The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients.

Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA.

Clin Nephrol. 2010 Jun;73(6):431-8.

PMID:
20497755
7.

The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.

Borazan A, Ustün H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A.

Mediators Inflamm. 2004 Jun;13(3):201-4.

8.

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.

Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.

Br J Dermatol. 2007 Jan;156(1):138-42.

PMID:
17199580
9.

Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.

Tarakçioğlu M, Erbağci AB, Usalan C, Deveci R, Kocabaş R.

Mediators Inflamm. 2003 Feb;12(1):15-9.

10.

High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.

Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A.

Nephrol Dial Transplant. 2001 Sep;16(9):1838-44.

PMID:
11522867
11.

Nutritional assessment of children on haemodialysis: value of IGF-I, TNF-alpha and IL-1beta.

Beşbaş N, Ozdemir S, Saatçi U, Coşkun T, Ozen S, Topaloğlu R, Bakkaloğlu A, El Nahas AM.

Nephrol Dial Transplant. 1998 Jun;13(6):1484-8.

PMID:
9641179
12.

The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.

Senel S, Kisacik B, Ugan Y, Kasifoglu T, Tunc E, Cobankara V.

Clin Rheumatol. 2011 Oct;30(10):1369-72. doi: 10.1007/s10067-011-1782-6. Epub 2011 May 28.

PMID:
21618077
13.
14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis.

Airaghi L, Garofalo L, Cutuli MG, Delgado R, Carlin A, Demitri MT, Badalamenti S, Graziani G, Lipton JM, Catania A.

Nephrol Dial Transplant. 2000 Aug;15(8):1212-6.

PMID:
10910447
16.

TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure.

van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, Loonen EH, Niesters HG, Zietse R, Weimar W.

Clin Nephrol. 2000 Feb;53(2):115-23.

PMID:
10711413
17.

Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.

Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I.

Rheumatology (Oxford). 2006 Jan;45(1):31-7. Epub 2005 Nov 15.

PMID:
16287931
18.

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.

Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.

Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22.

PMID:
18503600
19.

On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study.

Vaslaki LR, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D.

Artif Organs. 2005 May;29(5):406-12.

PMID:
15854217

Supplemental Content

Support Center